Viemed Healthcare, Inc.
VMDHealthcareNASDAQMedical Devices · Last scanned Sep 7, 2026
Scan Results
Daily timeframeViemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company carries a $345.8M market cap, placing it firmly in the small-cap category. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
Market Cap
$345.8M
Beta
1.09
P/E (TTM)
25.22
P/E (Fwd)
22.70
EPS (TTM)
$0.36
EPS (Fwd)
$0.40
ROE
10.4%
ROA
8.2%
Cash
$10.7M
Total Debt
$11.6M
Free CF
$28.3M
52W Change
32.2%
Annual Financials
Cash vs Debt
Where VMD stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, VMD finished 9.54% below its 150-day moving average ($9.75) and 2.86% below its 200-day moving average ($9.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VMD overbought or oversold?
At the August 31, 2026 close, VMD's RSI(14) was 38.7, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $10.7M in cash, though total debt stands at $11.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $28.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 10.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $138.8M (2022) to $270.3M (2025), reflecting a 95% increase over the period.
Investors considering Viemed Healthcare, Inc. should weigh the typical risks associated with VMD's sector, size, and financial profile against their own risk tolerance and investment objectives. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing VMD.